Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics.

Abstract

OBJECTIVE Patients with schizophrenia treated with antipsychotics often develop metabolic side effects including dyslipidemia. Antipsychotics potentially upregulate gene expression of a lipid metabolism pathway protein called SREBP via SREB transcription factors (SREBFs). Genetic variation within SREBF may contribute to dyslipidemias and lipid medication efficacy within schizophrenia. RESULTS A cross-sectional study of 157 patients were genotyped for SREBF1 (rs11868035) and SREBF2 (rs1057217) variants, and assessed for fasting lipids. The cohort's mean age was 46.6 years, was 64% male and 86% were using atypical antipsychotics. When stratified by statin use, those receiving a statin and carrying the SREBF1 T allele exhibited higher total cholesterol levels (p = 0.01), triglyceride levels (p = 0.04) and low-density lipoprotein levels (p = 0.03). A regression analysis controlling for gender differences in lipids showed that the SREBF1 T allele and statin interaction remained only for total cholesterol levels (F[4,149] = 5.8; p < 0.0001). CONCLUSION For schizophrenia individuals with the SREBF1 rs11868035 T allele, incomplete response to statin medications may be seen. Future investigations may allow for personalizing dyslipidemia treatment based on pharmacogenetics within schizophrenia.

DOI: 10.2217/pgs.13.157

Cite this paper

@article{Vassas2014PharmacogenomicsOS, title={Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics.}, author={Thomas J Vassas and Kyle J. Burghardt and Vicki L. Ellingrod}, journal={Pharmacogenomics}, year={2014}, volume={15 1}, pages={61-7} }